Encuity Repositions Syndicated Market Research Offerings as the Encuity Answer Suite™

NEWTOWN, Pa., Sept. 13, 2012 /PRNewswire/ -- Encuity Research, the market research and analytics subsidiary of Campbell Alliance, today announced the launch of its Encuity Answer Suite™.  This suite of seven syndicated market research audits is designed to provide reliable market insights to pharmaceutical and biotech companies regarding medical treatment and product promotion occurring at provider and consumer levels.

The Encuity Answer Suite™ renames industry-leading medical and promotional audits formerly offered by SDI Health and acquired from IMS Health in January 2012.

Encuity's existing suite of syndicated offerings will seamlessly transition to the Answer Suite™ as follows:

• The Physician Drug and Diagnosis Audit (PDDA) is now TreatmentAnswers—this audit provides national-level disease state and associated therapy data.
• The Personal Selling, Hospital Personal Selling, and NP/PA Audits (PSA/HPSA and NP/PA) are now DetailAnswers, with practioner levels that include office- and hospital-based physicians and NP/PAs—this audit delivers reliable estimates of competitive detailing activity by pharmaceutical companies to a variety of healthcare professionals.
• The Sample Distribution Audit (SDA) is now SampleAnswers—this audit monitors the volume and frequency of drug sampling to physician practices.
• The Physician Meeting & Event Audit (PMEA) is now EventAnswers—this audit tracks the meeting and event activities of all pharmaceutical companies and their respective products.
• The ePromotion Audit (ePromo) is now eAnswers—this audit provides competitive insights about online promotional activity across the pharmaceutical industry.
• The Professional Journal Audit (PJA) is now JournalAnswers—this audit provides estimates of pharmaceutical company advertising in professional medical journals and healthcare tabloids that target physicians and other healthcare professionals.
• The Direct-to-Consumer Advertising Audit (DTCA) is now ConsumerAnswers—this audit measures promotional spending for prescription products across most media types, including television, magazine, radio, newspaper, and outdoor advertising.

Additionally, the Online Report Generator tool, which has become an industry standard in audit access and reporting, has been renamed the online Answer Generator.

"Encuity Answer Suite™ audits have been refined for improved relevancy to customers; however, the scope of the audits remains unchanged," stated Michael Turner, General Manager of Encuity Research.  "In fact, their history, starting as early as 1989, will remain available through Encuity's online access site, the Answer Generator."

Encuity's Managed Care Promotional Audit (MCPA) has not been renamed and will be phased out in early 2013.

The company's existing Metropolitan Area Promotional Audit (MPA™) will continue to operate.  This audit service will be enhanced and integrated as part of the Encuity Answer Suite™ in late 2012.

For additional information on the Encuity Answer Suite™, including the coverage areas, frequency, delivery and timing of each audit, please visit: http://www.encuity.com/services/syndicated.

About Encuity Research
Encuity Research is the market research and analytics subsidiary of Campbell Alliance.  Encuity's team of skilled market research professionals provides answers that biopharmaceutical leaders need to make critical decisions at enterprise, portfolio, and product levels.  Its services span five key areas, including custom qualitative and quantitative market research and analytics, syndicated market research, promotional message tracking, and key opinion leader (KOL) influence mapping. For more information on Encuity and its services, please visit http://www.encuity.com.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is an industry leader in biopharmaceutical and medical technology consulting. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in New York City; Raleigh, NC; Parsippany, NJ; Somerset, NJ; Newtown, PA; Los Angeles; San Francisco; Chicago; Boston; Philadelphia; London; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance.  inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies.  With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality.  inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties;  the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

SOURCE Encuity Research